Abstract:The opioid system is one of the most studied pain relieving systems. Opioid peptides have been studied extensively since their discovery, and many efforts have been dedicated to the determination of their intrinsic nature. However, opioid peptides still suffer from serious limitations including lack of oral activity, short duration of action, poor metabolic stability, and relative inability to cross the blood-brain barrier (BBB). Inspired by the structure-activity studies of opioid peptides, four novel opioid dipeptides were synthesized by introduction of Tyr/Dmt to the N-termius and novel unnatural alpha-methylene-beta-amino acids (Map) to the C-terminus. Their in vitro and in vivo activities were determined and compared. The affinity and selectivity of these dipeptides were evaluated by radioligand binding assay in whole cell preparations from HEK293 cells expressing the delta opioid receptor (MOR) or d opioid receptor (DOR), compound 4 exhibited the highest binding affinity toward MOR, and this compound also showed the most significant MOR selectivity over DOR. Pharmacological activities were evaluated in vitro using isolated guinea pig ileum (GPI) for MOR and mouse vas deferens (MVD) for DOR, and the results of GPI and MVD were in accordance with the binding affinity assays. The antinociceptive activities of the compound 4 were assessed in the mouse tail-flick and writhing test after intracerebroventricular (i.c.v.) administration. In the two tests, compound 4 showed good ability to reduce the thermal pain and the inflammatory pain, respectively. Naloxone significantly reversed the activity of the compound, indicating that opioid receptors were involved in its analgesic effects. The compound 4 was then administered inravenously (i.v.) to determine whether this dipeptide was able to cross the BBB. As a result, compound 4 was effective in both tail-flick and writhing test after i.v. administration. Furthermore, the peripherally restricted opioid antagonist naloxone methiodide did not alter the peptide-induced antinociception. Collectively, these results indicated that compound 4 was able to cross the highly selective BBB and might elicit an analgesic response via a central mechanism. Therefore, compound 4 may be a potential lead compound for future clinical development for pain management.

BNT12, a Novel Hybrid Peptide of Opioid and Neurotensin Pharmacophores, Produces Potent Central Antinociception with Limited Side Effects

Spinal Administration of the Multi-Functional Opioid/neuropeptide FF Agonist BN-9 Produced Potent Antinociception Without Development of Tolerance and Opioid-Induced Hyperalgesia.

MEL-N16: A Series of Novel Endomorphin Analogs with Good Analgesic Activity and a Favorable Side Effect Profile

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

BN-9, a Chimeric Peptide with Mixed Opioid and Neuropeptide FF Receptor Agonistic Properties, Produces Nontolerance-Forming Antinociception in Mice.

Design, Synthesis, and In Vitro Characterization of Proteolytically-Stable Opioid-Neurotensin Hybrid Peptidomimetics

Design and Synthesis of a Novel Series of Opioid Dipeptides and Evaluation of Their Analgesic Effect in Vivo

Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators

Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking

The Multifunctional Peptide DN‐9 Produced Peripherally Acting Antinociception in Inflammatory and Neuropathic Pain Via Μ‐ and Κ‐opioid Receptors

The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via μ- and κ-opioid receptors.

Pharmacological Characterization of 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) As a Dual Selective MOR/KOR Ligand with Potential Applications in Treating Opioid Use Disorder.

Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities.

Systemic Administration of the Bifunctional Opioid/neuropeptide FF Receptors Agonist BN-9 Produced Peripheral Antinociception in Preclinical Mouse Models of Pain

Novel hybrid compounds, opioid agonist+melanocortin 4 receptor antagonist, as efficient analgesics in mouse chronic constriction injury model of neuropathic pain

Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog

A Novel Bifunctional μOR Agonist and σ1R Antagonist with Potent Analgesic Responses and Reduced Adverse Effects

Endomorphin-1 Analogues (mels) Penetrate the Blood–brain Barrier and Exhibit Good Analgesic Effects with Minimal Side Effects

Peripheral and Central Sites of Action for Anti-Allodynic Activity Induced by the Bifunctional Opioid/npff Receptors Agonist BN-9 in Inflammatory Pain Model

Evaluation of the systemic and spinal antinociceptive effect of a new hybrid NSAID tetrahydropyran derivative

All-Hydrocarbon Stapled Peptide Multifunctional Agonists at Opioid and Neuropeptide FF Receptors: Highly Potent, Long-Lasting Brain Permeant Analgesics with Diminished Side Effects.